– By Fred Dunlap – The Carnage continues…but do you have a moment for a Spot of Tea? Yes, this Newsletter has been described as a twice-monthly publication. And my goal is NOT to inundate you with too much information. But when unusual developments happen, like those in Britain and Europe last week, updates are needed […]

– By Fred Dunlap – While we were sleeping, the world changed. While we were tucked in bed, fifty-two percent of the citizens of Great Britain sent a message to the entire world. More directly, they put the European Union on notice that they would rather dance with a new devil, no matter how uncertain that […]

– By Fred Dunlap – Emotions are peaked and nerves are frayed in Great Britain as they near the anticipated Referendum vote this Thursday. Things in “Jolly Old England” are not so jolly these days. Four hundred years ago, a fairly well-known English poet wrote about an important question: “To be or not to be?” If […]

– By Fred Dunlap – With Memorial Day weekend now in our rear-view mirror, the Summer months are upon us. The exodus from lower Manhattan has officially begun, with bankers and investment pros swapping their city offices for their own personal remote office access somewhere out on Long Island. Historically, investors have used the adage “Sell […]

– By Fred Dunlap – The political process marches on. And we now have the cage match we have all been waiting for. Sure, there were other bidders along the way, but for the last month, it seemed inevitable that these two gladiators would be pitted against each other in a head-to-head battle. Adding to the intrigue, […]

– By Fred Dunlap – The Fed-Meisters held their ground today. They announced that the fed funds rate would remain the same at .25%. In their post-session report, they reconfirmed something which didn’t need reconfirmation: that they will be “data dependent” with any future actions. We have all been conditioned to that postulate for a while. […]

– By Fred Dunlap – Last week the subject of corporate inversions was again in the headlines. The long-awaited $160 billion deal between Pfizer and Allergan was abruptly scuttled due to a new ruling that was announced by the US Treasury. Treasury Secretary, Jack Lew, better known as the head of the Progress Prevention Team (PPT), […]